Published in Br J Cancer on April 01, 1994
(ADP-ribose)n participates in DNA excision repair. Nature (1980) 3.76
A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst (1980) 3.75
A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse. Br J Cancer (1976) 3.42
Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res (1981) 1.91
Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys (1986) 1.84
Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide. Br J Cancer (1981) 1.54
Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst (1990) 1.33
A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. Cancer Res (1977) 1.27
Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res (1989) 1.20
A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol (1991) 1.18
The enhancement of cytotoxicity of N-methyl-N-nitrosourea and of gamma-radiation by inhibitors of poly(ADP-ribose) polymerase. Eur J Biochem (1980) 1.17
Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer (1981) 1.13
Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys (1988) 1.08
Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol (1993) 1.06
Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.97
Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res (1990) 0.96
Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention. J Pharmacol Exp Ther (1972) 0.93
The absorption and excretion of pyrazinamide. I. Preliminary study in laboratory animals and in man. Am Rev Respir Dis (1968) 0.91
Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res (1985) 0.91
Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms. Br J Cancer (1984) 0.89
Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys (1989) 0.87
Potentiation of cell killing by inhibitors of poly(ADP-ribose) polymerase in four rodent cell lines exposed to N-methyl-N-nitrosourea or UV light. Chem Biol Interact (1982) 0.86
Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. Int J Radiat Oncol Biol Phys (1986) 0.86
Structure-activity relationships for tumour radiosensitization by analogues of nicotinamide and benzamide. Int J Radiat Biol (1991) 0.85
Radiosensitization effects of nicotinamide on malignant and normal mouse tissue. Cancer Res (1985) 0.84
Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide. Br J Cancer (1990) 0.83
The oxygenation of murine tumor isografts and human tumor xenografts by nicotinamide. Radiat Res (1992) 0.83
Enhancement of antitumor activity of bleomycin by benzamide in vitro and in vivo. J Antibiot (Tokyo) (1983) 0.82
Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status. Int J Radiat Oncol Biol Phys (1989) 0.81
Effect of nicotinamide analogues on recovery from DNA damage in C3H10T1/2 cells. Cancer Res (1984) 0.80
3-Aminobenzamide is lethal to MMS-damaged human fibroblasts primarily during S phase. J Cell Physiol (1984) 0.79
Enhancement of melphalan cytotoxicity in vivo and in vitro by inhibitors of poly (ADP-ribose) polymerase. Int J Radiat Oncol Biol Phys (1984) 0.79
Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice. Int J Radiat Oncol Biol Phys (1992) 0.78
Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. Br J Cancer (1986) 0.77
Tissue NAD levels and the response to irradiation of cytotoxic drugs. Br J Cancer (1970) 0.77
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 2.96
Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res (1987) 2.85
Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys (1986) 1.84
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res (1999) 1.79
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res (2001) 1.75
The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys (1989) 1.71
Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer (1985) 1.57
The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys (1987) 1.48
Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer (1985) 1.47
Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res (2001) 1.32
Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer (1999) 1.30
Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res (1989) 1.20
Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer (1989) 1.19
Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol (1995) 1.19
Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res (1998) 1.19
The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res (1995) 1.18
Tumour blood flow changes induced by application of electric pulses. Eur J Cancer (1999) 1.17
Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer (1993) 1.17
Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res (2000) 1.11
Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma. Int J Radiat Biol (1991) 1.10
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol (1998) 1.09
Targeting gene therapy to cancer: a review. Oncol Res (1997) 1.08
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer (2010) 1.07
Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol (1993) 1.06
Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol (1996) 1.06
Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer (1998) 1.05
Intermittent blood flow in the KHT sarcoma--flow cytometry studies using Hoechst 33342. Br J Cancer (1990) 1.04
Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer (2001) 1.03
Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res (1987) 1.01
Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer (2000) 0.99
Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res (2001) 0.99
Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration. Int J Radiat Oncol Biol Phys (1989) 0.98
Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer (1995) 0.98
The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res (2001) 0.97
Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br J Cancer (1990) 0.97
Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.97
Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed (1999) 0.97
Distribution of Photofrin between tumour cells and tumour associated macrophages. Br J Cancer (1991) 0.96
Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res (1990) 0.96
Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol (1999) 0.95
Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br J Cancer (2000) 0.95
The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours. Br J Cancer (1995) 0.94
Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res (1997) 0.94
Ischaemia induced cell death in tumors: importance of temperature and pH. Int J Radiat Oncol Biol Phys (1994) 0.94
Transient perfusion and radiosensitizing effect after nicotinamide, carbogen, and perflubron emulsion administration. Radiother Oncol (1996) 0.93
The effect of hypoxia and low pH on the cytotoxicity of chlorambucil. Int J Radiat Oncol Biol Phys (1992) 0.93
The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. Radiother Oncol (1994) 0.93
Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide. Cancer Res (1995) 0.93
Cell sorting with Hoechst or carbocyanine dyes as perfusion probes in spheroids and tumors. Methods Cell Biol (1990) 0.92
Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int J Radiat Oncol Biol Phys (1994) 0.92
Enhancement of chlorambucil cytotoxicity by combination with flavone acetic acid in a murine tumour. Anticancer Res (1994) 0.92
The influence of microenvironment on the cytotoxicity of TNF [symbol: see text] vitro. Int J Radiat Oncol Biol Phys (1994) 0.91
The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br J Cancer (1997) 0.91
Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug. Anticancer Drug Des (1998) 0.91
Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure. Int J Radiat Oncol Biol Phys (1992) 0.90
The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor. Int J Radiat Oncol Biol Phys (1986) 0.90
Tumour radiosensitization by high-oxygen-content gases: influence of the carbon dioxide content of the inspired gas on PO2, microcirculatory function and radiosensitivity. Int J Radiat Oncol Biol Phys (1998) 0.90
Photofrin uptake by murine macrophages. Cancer Res (1991) 0.89
Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma. Eur J Cancer (1991) 0.89
Measurement of tumor oxygenation: a comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat Res (1997) 0.89
Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. Radiother Oncol (1993) 0.88
The effects of hyperoxic and hypercarbic gases on tumour blood flow. Br J Cancer (1999) 0.88
Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol (1994) 0.88
Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer Suppl (1996) 0.87
Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Exp Physiol (1997) 0.87
Effect of carbogen breathing on tumour microregional blood flow in humans. Radiother Oncol (1996) 0.86
Inhibition of intracellular pH control and relationship to cytotoxicity of chlorambucil and vinblastine. Br J Cancer Suppl (1996) 0.86
Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT). Br J Cancer (1986) 0.85
The comparative effects of the NOS inhibitor, Nomega-nitro-L-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow. Int J Radiat Oncol Biol Phys (1998) 0.85
The response of mouse epidermis to fractionated doses of pi mesons. Int J Radiat Oncol Biol Phys (1987) 0.84
Human tumor blood flow is enhanced by nicotinamide and carbogen breathing. Cancer Res (1997) 0.83
The use of blood flow modifiers to improve the treatment response of solid tumors. Radiother Oncol (1991) 0.83
The effect of nicotinamide on microregional blood flow within tumours assessed using laser Doppler probes. Acta Oncol (1995) 0.83
Combination therapy of pions and SPG (Sonifilan, Schizophyllan), a biological response modifier for mouse tumor systems. Int J Radiat Oncol Biol Phys (1990) 0.83
Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother Oncol (1997) 0.83
Involvement of oxygen free radicals in ischaemia-reperfusion injury to murine tumours: role of nitric oxide. Free Radic Res (1998) 0.82
Cytotoxic effect of tumour necrosis factor -alpha on sarcoma F cells at tumour relevant oxygen tensions. Acta Oncol (1995) 0.82
Oxygen and nitroreductase-dependent binding of AF-2 in spheroids and murine tumors. Int J Radiat Oncol Biol Phys (1986) 0.82
Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status. Int J Radiat Oncol Biol Phys (1989) 0.81
Chemosensitization by misonidazole in CCNU-treated spheroids and tumours. Br J Cancer (1987) 0.81
Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification. Br J Cancer (1996) 0.80
Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res (1997) 0.80
The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. Radiother Oncol (1990) 0.80
Cytotoxicity of RSU 1069 in spheroids and murine tumors. Int J Radiat Oncol Biol Phys (1987) 0.80
Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Br J Cancer Suppl (1996) 0.80
Immune reaction induced by X-rays and pions and its stimulation by schizophyllan (SPG). Br J Cancer Suppl (1996) 0.80
Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA. Br J Cancer Suppl (1996) 0.80
Proportion of infiltrating IgG-binding immune cells predict for tumour hypoxia. Br J Cancer (2001) 0.79
Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy. Biomed Biochim Acta (1989) 0.79
Blood flow modification in the SCCVII tumor: effects of 5-hydroxytryptamine, hydralazine, and propranolol. Int J Radiat Oncol Biol Phys (1992) 0.79
Studies on the protection against misonidazole-induced toxicity by antiinflammatory agents. Adv Prostaglandin Thromboxane Leukot Res (1983) 0.79
Enhancement of mitomycin-C cytotoxicity by combination with flavone acetic acid in a murine tumour. Anticancer Res (1993) 0.78
Effect of endothelin-1 and sarafotoxin S6c on blood flow in a rat tumor. J Cardiovasc Pharmacol (1995) 0.78
Tumour blood flow modification by endothelin-related peptides in the rat HSN fibrosarcoma. Br J Cancer Suppl (1996) 0.78
Reoxygenation in a C3H mouse mammary carcinoma. The importance of chronic rather than acute hypoxia. Acta Oncol (1995) 0.78